Stock Surge – Talk Bio

Cogent Biosciences Soars on Positive Phase 3 PEAK Results in Gastrointestinal Stromal Tumors (GIST)

3 weeks ago talkbio0Tagged bezuclastinib, Clinical Trials, Cogent Biosciences, Frequency of Responses, Gastrointestinal Stromal Tumors, NDA, Phase 3, Progression-Free Survival, Standard (qualifier), Stock Surge, Submission, sunitinib

Cogent Biosciences; bezuclastinib; sunitinib; GIST; Phase 3; progression-free survival; objective response rate; NDA submission; clinical trial; stock surge; standard of care

Alnylam Surpasses $50B Market Cap as Amvuttra Heart Disease Launch Impresses Wall Street

4 months ago talkbio0Tagged Alnylam, Amvuttra, ATTR-CM, Caps, earnings, Heart Diseases, Market, revenue growth, Stock Surge

Alnylam Pharmaceuticals; market cap; Amvuttra; heart disease; ATTR-CM; stock surge; Q2 2025 earnings; revenue growth

GSK, Spero Report Major Phase 3 Win for UTI Antibiotic; Spero’s Stock Surges

6 months ago talkbio0Tagged Antibiotics, Clinical Trials, Complicated, HBr, PIVOT-PO trial, SmithKline Beecham, Spero Therapeutics, Stock Surge, Submission, United States Food and Drug Administration, Urinary tract infection

GSK; Spero Therapeutics; tebipenem HBr; Phase 3 trial; UTI antibiotic; complicated urinary tract infection; PIVOT-PO trial; stock surge; clinical trial results; FDA submission

Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

10 months ago talkbio0Tagged 22%, amycretin, Drug Industry, next-gen, Nordisk, Obesity, semaglutide, Stock Surge, Weight Loss

Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry

Sana Biotechnology’s Revolutionary Type 1 Diabetes Therapy Triggers Stock Surge

11 months ago talkbio0Tagged Diabetes, Hypoimmune Technology, Immune-Evading Therapy, Sana Biotechnology, Stock Surge

Sana Biotechnology, Type 1 Diabetes, Immune-Evading Therapy, Stock Surge, Hypoimmune Technology

Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy

1 year ago talkbio0Tagged apitegromab, Biologics License Application, MAA, Phase 3 Clinical Trials, Scholar Rock, SMA, Spinal Muscular Atrophy, Stock Surge

Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)